Vaxcyte Highlights Progress on Pneumonia Vaccine Pipeline

Biotech company provides updates on late-stage development, manufacturing, and future plans for its pneumococcal conjugate vaccine and Group A Strep program.

Feb. 28, 2026 at 1:08am

Got story updates? Submit your updates here. ›

Vaxcyte, a clinical-stage biotech company focused on developing a new generation of preventive vaccines, used its Q4 2025 earnings call to highlight progress on its pneumococcal conjugate vaccine (PCV) franchise and plans to restart development of its Group A Strep vaccine candidate. The company discussed the design and enrollment of its pivotal OPUS Phase 3 studies for its lead PCV candidate, VAX-31, as well as manufacturing investments and commercial launch preparations. Vaxcyte also outlined plans to initiate a Phase 1 study for its VAX-A1 Group A Strep vaccine in 2026.

Why it matters

Pneumococcal disease remains a significant global health burden, and Vaxcyte believes its broader-coverage PCV candidate can address gaps in serotype protection from existing vaccines. The company's progress on late-stage development and manufacturing capacity building positions it to potentially bring a new PCV option to market, which could improve prevention of serious pneumococcal infections. Restarting the Group A Strep program also signals Vaxcyte's commitment to expanding its pipeline of novel preventive vaccines.

The details

Vaxcyte's PCV candidate, VAX-31, is designed to protect against 31 serotypes of Streptococcus pneumoniae. The company has finalized the Phase 3 OPUS program in consultation with the FDA, which includes three trials (OPUS-1, -2, and -3) expected to enroll around 6,000 adults to evaluate safety, tolerability, and immunogenicity. Vaxcyte has also completed construction of a dedicated large-scale manufacturing facility and is investing up to $1 billion in U.S. production capacity to support global commercial demand. On the Group A Strep front, Vaxcyte plans to initiate a Phase 1 adult study for its VAX-A1 candidate in 2026, focused on safety, tolerability, and immunogenicity.

  • Vaxcyte reported final data from the VAX-24 Phase 2 infant dose-finding study in November 2025.
  • Enrollment is complete for the ongoing VAX-31 infant Phase 2 study, with 900 infants dosed.
  • Vaxcyte expects to announce top-line data for the VAX-31 infant study's primary three-dose series and booster dose by the end of the first half of 2027.
  • Vaxcyte plans to initiate a Phase 1 adult study for its VAX-A1 Group A Strep vaccine candidate in 2026.

The players

Vaxcyte, Inc.

A clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California.

Grant Pickering

Chief Executive Officer of Vaxcyte.

Jim Wassil

Executive Vice President and Chief Operating Officer of Vaxcyte.

Andrew Guggenhime

Chief Financial Officer of Vaxcyte.

Mike Miletich

Chief Commercial Officer of Vaxcyte.

Got photos? Submit your photos here. ›

What they’re saying

“Pneumococcal disease continues to cause substantial morbidity and mortality globally, and gaps in serotype coverage persist despite existing vaccines.”

— Grant Pickering, Chief Executive Officer

“The OPUS studies are designed to generate a broad safety, tolerability, and immunogenicity data set across adult populations and real-world vaccination scenarios.”

— Jim Wassil, Executive Vice President and Chief Operating Officer

“We are seeing early signals in the 50–64 age segment following the expanded U.S. recommendation, while noting that immunizations in that group may have been lower in the year due to lower influenza vaccination rates in Q4.”

— Mike Miletich, Chief Commercial Officer

What’s next

Vaxcyte is evaluating whether unblinding and disclosing the primary series (PD3) data from the VAX-31 infant Phase 2 study earlier could provide operating benefits, such as enabling earlier FDA engagement or allowing Phase 3 initiation sooner. The company expects an update on its unblinding and disclosure plans by mid-2026.

The takeaway

Vaxcyte's progress on its pneumococcal conjugate vaccine pipeline, including the design and enrollment of pivotal Phase 3 trials, manufacturing capacity expansion, and plans to restart its Group A Strep program, demonstrate the company's commitment to developing a new generation of preventive vaccines to address significant unmet medical needs in infectious disease.